Keith Wille
Critical Care Medicine · Birmingham, ALNPI 1285658336
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Vantive US Healthcare LLC accounts for 63.0% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $6,438, 7.7 times the $837 reported in 2019. Among critical care medicine clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $165.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vantive US Healthcare LLC$6K
- Nxstage Medical, Inc.$570
- Paragonix Technologies, Inc.$395
- AstraZeneca$375
- Astellas Pharma US Inc$357
- La Jolla Pharmaceutical Company$319
- plus $1K from 10 others
Across 3 payments — averaging $16,783 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$50K
What the payments were for
- Travel & lodging$1,52416%
- Food & beverage$3,76541%
- Education$4,00043%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vantive US Healthcare LLC | 12 | $5,854 |
| Nxstage Medical, Inc. | 5 | $570 |
| Paragonix Technologies, Inc. | 4 | $395 |
| AstraZeneca | 3 | $375 |
| Astellas Pharma US Inc | 3 | $357 |
| La Jolla Pharmaceutical Company | 7 | $319 |
| Baxter Healthcare | 5 | $291 |
| Insmed, Inc. | 2 | $245 |
| Fresenius USA Marketing, Inc. | 3 | $224 |
| Mayne Pharma Commercial LLC | 2 | $153 |
| AbbVie(2 entities) | 5 | $142 |
| Abiomed | 1 | $130 |
| Inari Medical, Inc. | 1 | $113 |
| Mallinckrodt Enterprises LLC | 1 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| GSK | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Acute$5,597
- NOVALUNG SYSTEM$545
- FASENRA$375
- CRESEMBA$357
- SherpaPak$235
- BaroGuard$235
- LUNGguard$235
- Arikayce$144
- DORYX$122
- Zevtera$122
- NXSTAGE SYSTEM ONE$115
- FLOWTRIEVER CATHETER, S$113
- CT THROMBECTOMY SYSTEM KIT$113
- AVYCAZ$105
- Renal - Non Product Related$102
How this compares
$9,289 in reported general payments places this provider in the 90th percentile of 73 critical care medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $42,167 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $29,003 |
| EliquisApixaban | 16 | $10,008 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $8,941 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $4,243 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,730 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $2,428 |
| Mycophenolic AcidMycophenolate Sodium | 12 | $1,026 |
| Dapsone | 15 | $977 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $423 |
| Azithromycin | 20 | $416 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $378 |
| Fluticasone Propionate | 18 | $341 |
| Prednisone | 52 | $306 |
| Doxycycline Hyclate | 31 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $17 | $82,841126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 critical care medicine providers in Alabama.
Other critical care medicine in Birmingham
- James WellsBirmingham$223K
- Mark DransfieldBirmingham$160K
- George SolomonBirmingham$113K
- Tracy LuckhardtBirmingham$28K
- Victor ThannickalBirmingham$8K
- Vipul ShahBirmingham$6K
- Samuel McElweeBirmingham$5K
- Nicole SchreinerBirmingham$4K
- David LafonBirmingham$4K
- Dhaval RavalBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.